In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival

Chronic lymphocytic leukemia (CLL) cells are highly dependent on microenvironmental cells and signals. The lymph node (LN) is the critical site of in vivo CLL proliferation and development of resistance to both chemotherapy and targeted agents. We present a new model that incorporates key aspects of the CLL LN, which enables investigation of CLL cells in the context of a protective niche. We describe a three-dimensional (3D) in vitro culture system using ultra-low attachment plates to create spheroids of CLL cells derived from peripheral blood. Starting from CLL:T cell ratios as observed in LN samples, CLL activation was induced by either direct stimulation and/or indirectly via T cells. Compared with two-dimensional cultures, 3D cultures promoted CLL proliferation in a T cell-dependent manner, and enabled expansion for up to 7 weeks, including the formation of follicle-like structures after several weeks of culture. This model enables high-throughput drug screening, of which we describe response to Btk inhibition, venetoclax resistance, and T cell-mediated cytotoxicity as examples. In summary, we present the first LN-mimicking in vitro 3D culture for primary CLL, which enables readouts such as real-time drug screens, kinetic growth assays, and spatial localization. This is the first in vitro CLL system that allows testing of response and resistance to venetoclax and Bruton's tyrosine kinase inhibitors in the context of the tumor microenvironment, thereby opening up new possibilities for clinically useful applications.

[1]  Š. Pospíšilová,et al.  RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model , 2021, International journal of molecular sciences.

[2]  Christopher I. Jones,et al.  TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target. , 2021, Blood.

[3]  A. Kater,et al.  Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? , 2020, Frontiers in Oncology.

[4]  F. Sbrana,et al.  Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents , 2020, Haematologica.

[5]  S. Fernandes,et al.  Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. , 2020, Blood.

[6]  C. Connine,et al.  inhibition , 2020, Catalysis from A to Z.

[7]  Catherine J. Wu,et al.  Clonal dynamics in chronic lymphocytic leukemia. , 2019, Blood advances.

[8]  R. de Boer,et al.  Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. , 2019, Blood advances.

[9]  C. Ziegler,et al.  Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia , 2019, Cell reports.

[10]  L. Miguet,et al.  BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo , 2019, Scientific Reports.

[11]  L. Staudt,et al.  TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. , 2018, Cancer research.

[12]  Xiao-Jie Yan,et al.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion , 2018, The Journal of Immunology.

[13]  W. Luyten,et al.  Three‐dimensional cell culture models for anticancer drug screening: Worth the effort? , 2018, Journal of cellular physiology.

[14]  A. Kater,et al.  Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk , 2017, Haematologica.

[15]  A. Kater,et al.  Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition , 2017, Leukemia.

[16]  Sonali M. Smith,et al.  Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib , 2015, Oncotarget.

[17]  U. Klein,et al.  Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. , 2014, Blood.

[18]  N. Chiorazzi,et al.  B cell receptor signaling in chronic lymphocytic leukemia. , 2013, Trends in immunology.

[19]  E. Remmerswaal,et al.  IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. , 2013, Blood.

[20]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[21]  M. Minden,et al.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling , 2012, Nature.

[22]  C. Geest,et al.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.

[23]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.

[24]  C. Doglioni,et al.  Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. , 2011, Seminars in diagnostic pathology.

[25]  T. Kipps,et al.  Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles , 2011, Leukemia.

[26]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[27]  A. Kater,et al.  Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering , 2010, Oncogene.

[28]  C. Peschel,et al.  Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors , 2010, Annals of Hematology.

[29]  M. Piris,et al.  Proliferation centers in chronic lymphocytic leukemia: the niche where NF-κB activation takes place , 2010, Leukemia.

[30]  Nienke Vrisekoop,et al.  In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. , 2008, Cancer research.

[31]  A. Kater,et al.  c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. , 2008, Blood.

[32]  A. Rosenwald,et al.  High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. , 2007, Blood.

[33]  Annelieke Jaspers,et al.  Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. , 2007, Blood.

[34]  M. Gobbi,et al.  Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. , 2006, Blood.

[35]  T. Kipps,et al.  Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. , 2002, Blood.

[36]  F. Sallusto,et al.  Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 , 2002, European journal of immunology.

[37]  C. Peschel,et al.  Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. , 2000, Blood.

[38]  P. Griebel,et al.  CD40 signaling induces B cell responsiveness to multiple members of the gamma chain-common cytokine family. , 1999, International immunology.

[39]  Ondřej Chum,et al.  CENTER FOR , 2001 .